<TEXT>&#2;<DATELINE>2018-05-30</DATELINE><TITLE>Norbert Bischofberger</TITLE><BODY>Norbert Bischofberger, former CSO of Gilead, discusses antiviral opportunities, Gilead's pivot to oncology and the need for a societal discussion of drug costs.&#3;</BODY></TEXT>